Pay in 4 interest-free payments of $6.69 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Effect and safety of semaglutide compared with dulaglutide and exenatide ER in subjects with type 2 diabetes (SUSTAIN 10)
Phase 2 body composition substudy data using DEXA scans showed that retatrutide participants lost predominantly fat mass, with a favorable fat-to-lean mass loss ratio
The FDA and the EMA have not reached a final conclusion regarding such a causal relationship
GLP-1 therapies have demonstrated substantial weight-reduction benefits, with studies showing an average weight loss of 4.6 kg, a BMI reduction of 2.1 kg/m, and a decrease in waist circumference of 4.6 cm compared to placebo
US$ 22.54
US$ 29.95
US$ 22.89
US$ 26.57
US$ 29.73
US$ 27.62
US$ 28.45
